Epoetin alfa: Difference between revisions
Matt Pijoan (talk | contribs) m Protected "Epoetin alfa": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +) |
||
| Line 23: | Line 23: | ||
{{CMG}} | {{CMG}} | ||
'''Epoetin alfa''' ([[International Nonproprietary Name|rINN]]) ({{pronEng|ɛˈpoʊɨtɨn}}) is a synthetic form of [[erythropoietin]]. It stimulates [[erythropoiesis]] (increases [[red blood cell]] levels) and is used to treat [[anemia]], commonly associated with [[chronic renal failure]] and cancer [[chemotherapy]]. Epoetin is marketed under the trade names '''Procrit''' and '''Epogen'''. | '''Epoetin alfa''' ([[International Nonproprietary Name|rINN]]) ({{pronEng|ɛˈpoʊɨtɨn}}) is a synthetic form of [[erythropoietin]]. It stimulates [[erythropoiesis]] (increases [[red blood cell]] levels) and is used to treat [[anemia]], commonly associated with [[chronic renal failure]] and cancer [[chemotherapy]]. Epoetin is marketed under the trade names '''Procrit''' and '''Epogen'''. | ||
| Line 37: | Line 37: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 02:20, 9 August 2012
| Identifiers | |
|---|---|
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
|
WikiDoc Resources for Epoetin alfa |
|
Articles |
|---|
|
Most recent articles on Epoetin alfa Most cited articles on Epoetin alfa |
|
Media |
|
Powerpoint slides on Epoetin alfa |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Epoetin alfa at Clinical Trials.gov Clinical Trials on Epoetin alfa at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Epoetin alfa
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Epoetin alfa Discussion groups on Epoetin alfa Patient Handouts on Epoetin alfa Directions to Hospitals Treating Epoetin alfa Risk calculators and risk factors for Epoetin alfa
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Epoetin alfa |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Epoetin alfa (rINN) (Template:PronEng) is a synthetic form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy. Epoetin is marketed under the trade names Procrit and Epogen.
See also
External links
References
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs
- Growth factors
- Erythropoiesis-stimulating agents